Levosimendan in acute heart failure: Past, present and future;Levosimendán en la insuficiencia cardiaca aguda: Pasado, presente y futuro

Revista Espanola de Cardiologia

Volumn 59, Issue 4, 2006, Pages 309-312

  Delgado, Juan F ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; DOBUTAMINE; INOTROPIC AGENT; LEVOSIMENDAN; PLACEBO; TROPONIN C; VASODILATOR AGENT;

ACUTE HEART FAILURE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ACTIVITY; DRUG INDICATION; DRUG MECHANISM; EDITORIAL; EVIDENCE BASED MEDICINE; HEART ATRIUM ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HEART HEMODYNAMICS; HEART INDEX; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTENSION; INOTROPISM; META ANALYSIS; MORBIDITY; MORTALITY; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33744787056     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13087053     Document Type: Editorial

References (19)

1. Nieminen MS, Bohm M, Cowie MR, Drexler H, Fillippatos GS, Jondeau G et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Rev Esp Cardiol. 2005;58:389-429.
2. Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002;4:515-29.
3. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-7.
4. Crespo Leiro M, Paniagua Martín M. Tratamiento de la insuficiencia cardíaca refractaria o avanzada. Rev Esp Cardiol. 2004; 57:869-83.
5. Tamargo J, López-Sendón J. Bases y evidencias clínicas de los efectos de los nuevos tratamientos farmacológicos en la insuficiencia cardíaca. Rev Esp Cardiol. 2004;57:447-64.
6. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation. 2000;102:2222-7.
7. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation. 2005;111:1504-9.
8. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196-202.
9. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003;107:81-6.
10. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422-32.
11. Coletta AP, Cleland JGF, Freemantle N, Clark AL. Clinical trials update from the European Society of Cardiology Heart Failure meeting: SHAPE, BRING-UP 2 VAS, COLA II, FOSIDIAL, BETACAR, CASINO and meta-analysis of cardiac resynchronisation therapy. Eur J Heart Fail. 2004;6:673-6.
12. Siirilä-Waris K, Suojaranta-Ylinen R, Harjola V-P. Levosimendan in Cardiac Surgery. J Cardiothorac Vasc Anesth. 2005;19:345-9.
13. Álvarez J, Bouzada M, Fernández AL, Caruezo V, Taboada M, Rodríguez J, et al. Comparación de los efectos hemodinámicos del levosimendán con la dobutamina en pacientes con bajo gasto después de cirugía cardiaca. Rev Esp Cardiol. 2006;59:338-45.
14. Bermejo J, Segovia J, Alfonso F. Resúmenes de los ensayos clínicos presentados en las Sesiones Científicas de la American Heart Association 2005 (Dallas, Texas, Estados Unidos, 13-16 noviembre 2005). Rev Esp Cardiol. 2006;59:143-53.
15. Cleland JGF, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8:105-10.
16. Silva Cardoso J, Ferreira J, Prazeres de Sá E, Martins de Campos J, Fonseca C, Lousada N, et al. O levosimendan na prática quotidiana de cuidados intensivos. Fundamentação, métodos e organização do Estudo Portland. Rev Port Cardiologia. 2004;23:1431-43.
17. Follath F, Franco F, Cardoso JS. European experience on the practical use of levosimendan in patients with acute heart failure syndromes. Am J Cardiol. 2005;96:80-5.
18. Parissis JT, Filippatos G, Farmakis D, Adamopoulos S, Paraskevaidis I, Kremastinos D. Levosimendan for the treatment of acute heart failure syndromes. Expert Opin Pharmacother. 2005;6:2741-51.
19. Rao V, Ivanov J, Weisel RD, Ikonomidis JS, Christakis GT, David TE. Predictors of low cardiac output syndrome after coronary artery bypass. J Thorac Cardiovasc Surg. 1996;112:38-51.